Overall verdict
Neutral
5.6/10
1-year performance
+43.86%
Score breakdown
Up 43.9% over 1 year, 98% of the 52-week range.
Strongest: Shareholder return 9.3/10. Weakest: Profitability 4.5/10.
16 analysts, target +0.1% vs the price.
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems ;
IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system ; hemodynamic monitoring system ; and prefillable drug delivery systems. It also offers specimen and blood collection products ;
automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products ; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Thomas Polen
Founded
1897
Employees
72 000
Revenue / employee
280 875 USD
Next earnings
February 4, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.97%
- Bank of New York Mellon Corp0.64%
- FMR LLC0.22%
- Rest of the register96.17%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
216.74 USD
52-week low
140.11 USD
1-year performance
43.86%
Rising
Year-to-date performance
40.77%
Rising
Drawdown
-0.83%
Near its high
Position in the 52-week range
98% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 1.3 times harder: once that risk is counted, it did about as well as the ETF.
$10,000 placed at the end of December 2000 are worth today
| Becton | $112,822 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.3 times as much as the world ETF.
- Worst fall:-40 % between July 2023 and May 2025. $10,000 placed at the top fell to $5,994. The world ETF, at worst: -53 %. The share has not returned to its high yet.
Becton earned more than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Becton: $112,822
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 98.21 USD - 204.44 USD (comparables only)
The price implies growth of 6.09% per year; the company grows at -9.81%.
Gross margin 55.9%, net margin 7.4%, ROIC 3.6%, ROE 6.0%.
Net margin
7.38%
Fair
Sector 9.34%|S&P 13.40%
Gross margin
55.95%
Fair
Return on equity (ROE)
5.96%
Fair
Sector 7.45%|S&P 17.06%
Return on invested capital (ROIC)
3.65%
Low
Free cash flow margin (FCF)
13.32%
High
Profit-to-cash conversion (FCF conversion)
1.80x
Exceptional
Margin stability
2.4 pts
Steady
Revenue to net income
Growth
5.1/10Revenue down 10.5% over 1 year, 0.3% a year over 5, EPS -9.8% a year over 5.
Revenue (trailing 12 months)
20.2Md USD
Revenue growth (1y)
-10.46%
Declining
Revenue growth (3y)
0.44%
Moderate
EPS growth (1y)
47.91%
Hyper-growth
EPS CAGR (5y)
-9.81%
Declining
EPS revisions (3 months)
-0.69%
Revised down
Valuation
4.9/10P/E 51.9x, forward P/E 29.2x, EV/EBITDA 15.0x, PEG 1.08. The multiple sits in the 100th percentile of its own 5-year history.
P/E (TTM)
51.9x
Expensive
Sector 29.2x|S&P 23.6x
Forward P/E
29.2x
Fair
EV / EBITDA
15.0x
Fair
Sector 14.4x|S&P 15.5x
PEG
1.08
Fair
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
151.33 USD
Overvalued
P/E vs its own 5-year history
among the 1% highest valuations
At its historical high
Market cap
58.5Md USD
Financial strength
4.8/10Cash covers 6.2% of the debt, net debt/EBITDA 2.9x.
Net debt / EBITDA
2.9x
Stretched
Gearing (net debt / equity)
62.10%
Tight
Cash
1.0Md USD
Cash / market cap
1.74%
Stretched
Cash / total debt
6.22%
Stretched
Interest coverage
4.2x
Tight
Net debt
15.3Md USD
Equity
24.7Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 212.61 USD
- MM20199.73
- MM50189.21
- MM200169.82
- RSI 1471.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.16%
200-day average slope, 3 months
-0.94%
50-day average slope, 1 month
+3.73%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.71 % per day
Volatility change
+0.09%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 7.36 (4) | 13.22 (14) | 19 796 (13) | 5 828 (6) | 2 010 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 10, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK | 6.5 | 6.1 | 121Md USD | 34.0x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -10.5 % | ||
| 2 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.2 % | ||
| 3 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 4 | MDT | 6.2 | 6.7 | 130Md USD | 25.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 9.3 % | ||
| 5 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 6 | EW | 5.9 | 5.1 | 60.8Md USD | 61.6x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 25.3 % | ||
| 7 | BDX | 5.6 | 5.3 | 58.5Md USD | 51.9x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 43.9 % | ||
| 8 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 9 | SHL | 5.3 | 5.3 | 53.1Md USD | 22.0x | 9.4 % | 7.3 % | 7.3 % | 2.8x | 4.3 % | 0.0 % |
